October - December 2011

December 28, 2011		Takeda Well-Being Program 2011 - "Giving Children in Long-term Treatment the Energy to Live"
December 21, 2011		FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
December 21, 2011		Takeda Announces Change in Managements with the Establishment of New Organization
December 21, 2011		Establishment of Takeda California, Inc.by Integration of Takeda San Diego, Inc. and Takeda San Francisco, Inc.
December 21, 2011		Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
December 20, 2011		Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE® in the Treatment of Lymphoma
December 16, 2011		Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan
December 14, 2011		Presentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma
December 14, 2011		Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRISTM (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
December 13, 2011		Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRISTM (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting
December 13, 2011		Overall Survival Benefit with VELCADE® based Therapy in Previously Untreated Multiple Myeloma Patients Maintained after Five Year Follow-Up
December 9, 2011		Takeda's Edarbi® (azilsartan medoxomil) receives European marketing authorisation for the treatment of essential hypertension
December 8, 2011		FDA ADVISORY COMMITTEE VOTED IN FAVOR OF BENEFIT/RISK PROFILE FOR PEGINESATIDE FOR TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS ON DIALYSIS
December 5, 2011		Takeda to Launch Global Vaccine Business
December 5, 2011		Takeda Announces Change in Management with the Establishment of New Organization
December 1, 2011		Overflow of Contaminated Water at Shonan Research Center
November 24, 2011		Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
November 18, 2011		U.S. Food and Drug Administration (FDA) Delays Review of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
November 16, 2011		Quadrivalent Vaccine TAK-361S Enters into Phase II Clinical Trials in Japan
November 9, 2011		Seattle Genetics and Millennium Announce Presentation of ADCETRISTM Data at American Society of Hematology Annual Meeting
November 9, 2011		More than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting
November 4, 2011		Takeda Announces the Revision of the Consolidated Financial Forecasts for Fiscal 2011
November 4, 2011		New Structure of Business Operations for a Global Pharmaceutical Company
November 4, 2011		Takeda Announces New Assignment of Directors and Corporate Officers
November 4, 2011		Takeda Announces the Conclusion of the Mutual Agreement Procedure Relating to the Correction Notice on Transfer Pricing and Recommencement of the Reinvestigation Process
November 2, 2011		FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE® in Patients with Previously Untreated Multiple Myeloma
October 21, 2011		Further European Regulatory Review Clarifies and Confirms Prior CHMP Position on Positive Benefit-Risk Balance for Pioglitazone-Containing Products
October 18, 2011		Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
October 11, 2011		Brentuximab Vedotin Enters Phase 1/2 Clinical Trial in Japan
October 7, 2011		Takeda Discontinues Development of Ramelteon in Europe for the Treatment of Insomnia
October 6, 2011		Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma
October 1, 2011		Takeda Announces New Assignment of a Director and Corporate Officers, Including Change of the Organization Name
October 1, 2011		Takeda completes acquisition and names new CEO of Nycomed